nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP2C18—Diphenhydramine—atopic dermatitis	0.0875	0.123	CbGbCtD
Buprenorphine—CYP3A7—Tacrolimus—atopic dermatitis	0.0397	0.0557	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Tacrolimus—atopic dermatitis	0.0397	0.0557	CbGbCtD
Buprenorphine—CYP2C8—Mometasone—atopic dermatitis	0.0365	0.0512	CbGbCtD
Buprenorphine—CYP3A5—Tacrolimus—atopic dermatitis	0.0298	0.0418	CbGbCtD
Buprenorphine—CYP2A6—Prednisolone—atopic dermatitis	0.025	0.035	CbGbCtD
Buprenorphine—ABCG2—Hydrocortisone—atopic dermatitis	0.0219	0.0307	CbGbCtD
Buprenorphine—CYP2C8—Loratadine—atopic dermatitis	0.021	0.0294	CbGbCtD
Buprenorphine—CYP3A4—Pimecrolimus—atopic dermatitis	0.0195	0.0274	CbGbCtD
Buprenorphine—ABCB1—Tacrolimus—atopic dermatitis	0.0194	0.0272	CbGbCtD
Buprenorphine—CYP2C19—Loratadine—atopic dermatitis	0.0176	0.0247	CbGbCtD
Buprenorphine—CYP2C19—Diphenhydramine—atopic dermatitis	0.0176	0.0247	CbGbCtD
Buprenorphine—CYP1A2—Diphenhydramine—atopic dermatitis	0.0162	0.0228	CbGbCtD
Buprenorphine—CYP3A7—Hydrocortisone—atopic dermatitis	0.0162	0.0227	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Hydrocortisone—atopic dermatitis	0.0162	0.0227	CbGbCtD
Buprenorphine—CYP2A6—Dexamethasone—atopic dermatitis	0.0147	0.0206	CbGbCtD
Buprenorphine—CYP2C9—Loratadine—atopic dermatitis	0.0146	0.0205	CbGbCtD
Buprenorphine—CYP2C9—Diphenhydramine—atopic dermatitis	0.0146	0.0205	CbGbCtD
Buprenorphine—ABCB1—Loratadine—atopic dermatitis	0.0142	0.0199	CbGbCtD
Buprenorphine—ABCG2—Dexamethasone—atopic dermatitis	0.0136	0.0191	CbGbCtD
Buprenorphine—CYP2D6—Loratadine—atopic dermatitis	0.0134	0.0188	CbGbCtD
Buprenorphine—CYP2D6—Diphenhydramine—atopic dermatitis	0.0134	0.0188	CbGbCtD
Buprenorphine—ABCB1—Methylprednisolone—atopic dermatitis	0.013	0.0182	CbGbCtD
Buprenorphine—CYP3A5—Hydrocortisone—atopic dermatitis	0.0121	0.017	CbGbCtD
Buprenorphine—CYP2C8—Hydrocortisone—atopic dermatitis	0.0117	0.0164	CbGbCtD
Buprenorphine—CYP3A4—Tacrolimus—atopic dermatitis	0.0116	0.0163	CbGbCtD
Buprenorphine—CYP3A7—Dexamethasone—atopic dermatitis	0.0101	0.0141	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Dexamethasone—atopic dermatitis	0.0101	0.0141	CbGbCtD
Buprenorphine—CYP2C19—Prednisone—atopic dermatitis	0.00975	0.0137	CbGbCtD
Buprenorphine—CYP3A4—Loratadine—atopic dermatitis	0.00851	0.0119	CbGbCtD
Buprenorphine—ABCB1—Betamethasone—atopic dermatitis	0.00844	0.0118	CbGbCtD
Buprenorphine—ABCB1—Prednisolone—atopic dermatitis	0.00833	0.0117	CbGbCtD
Buprenorphine—ABCB1—Hydrocortisone—atopic dermatitis	0.0079	0.0111	CbGbCtD
Buprenorphine—ABCB1—Prednisone—atopic dermatitis	0.00787	0.011	CbGbCtD
Buprenorphine—CYP3A4—Methylprednisolone—atopic dermatitis	0.00778	0.0109	CbGbCtD
Buprenorphine—CYP3A5—Dexamethasone—atopic dermatitis	0.00755	0.0106	CbGbCtD
Buprenorphine—CYP2C8—Dexamethasone—atopic dermatitis	0.00725	0.0102	CbGbCtD
Buprenorphine—CYP2C19—Dexamethasone—atopic dermatitis	0.00609	0.00854	CbGbCtD
Buprenorphine—CYP3A4—Triamcinolone—atopic dermatitis	0.0059	0.00827	CbGbCtD
Buprenorphine—CYP2C9—Dexamethasone—atopic dermatitis	0.00506	0.0071	CbGbCtD
Buprenorphine—CYP3A4—Betamethasone—atopic dermatitis	0.00506	0.00709	CbGbCtD
Buprenorphine—CYP3A4—Prednisolone—atopic dermatitis	0.00499	0.007	CbGbCtD
Buprenorphine—ABCB1—Dexamethasone—atopic dermatitis	0.00491	0.00689	CbGbCtD
Buprenorphine—CYP3A4—Hydrocortisone—atopic dermatitis	0.00473	0.00663	CbGbCtD
Buprenorphine—CYP3A4—Prednisone—atopic dermatitis	0.00471	0.00661	CbGbCtD
Buprenorphine—CYP2D6—Dexamethasone—atopic dermatitis	0.00463	0.00649	CbGbCtD
Buprenorphine—CYP3A4—Dexamethasone—atopic dermatitis	0.00294	0.00413	CbGbCtD
Buprenorphine—Headache—Tacrolimus—atopic dermatitis	8.95e-05	0.000386	CcSEcCtD
Buprenorphine—Oedema—Hydrocortisone—atopic dermatitis	8.92e-05	0.000384	CcSEcCtD
Buprenorphine—Anaphylactic shock—Hydrocortisone—atopic dermatitis	8.92e-05	0.000384	CcSEcCtD
Buprenorphine—Convulsion—Triamcinolone—atopic dermatitis	8.91e-05	0.000384	CcSEcCtD
Buprenorphine—Tachycardia—Prednisolone—atopic dermatitis	8.91e-05	0.000384	CcSEcCtD
Buprenorphine—Convulsion—Methylprednisolone—atopic dermatitis	8.89e-05	0.000383	CcSEcCtD
Buprenorphine—Hypertension—Triamcinolone—atopic dermatitis	8.88e-05	0.000383	CcSEcCtD
Buprenorphine—Hypertension—Methylprednisolone—atopic dermatitis	8.86e-05	0.000382	CcSEcCtD
Buprenorphine—Infection—Hydrocortisone—atopic dermatitis	8.86e-05	0.000382	CcSEcCtD
Buprenorphine—Hyperhidrosis—Prednisolone—atopic dermatitis	8.82e-05	0.00038	CcSEcCtD
Buprenorphine—Shock—Hydrocortisone—atopic dermatitis	8.77e-05	0.000378	CcSEcCtD
Buprenorphine—Myalgia—Triamcinolone—atopic dermatitis	8.76e-05	0.000377	CcSEcCtD
Buprenorphine—Nervous system disorder—Hydrocortisone—atopic dermatitis	8.74e-05	0.000377	CcSEcCtD
Buprenorphine—Arthralgia—Methylprednisolone—atopic dermatitis	8.74e-05	0.000377	CcSEcCtD
Buprenorphine—Myalgia—Methylprednisolone—atopic dermatitis	8.74e-05	0.000377	CcSEcCtD
Buprenorphine—Eye disorder—Prednisone—atopic dermatitis	8.73e-05	0.000376	CcSEcCtD
Buprenorphine—Anxiety—Methylprednisolone—atopic dermatitis	8.71e-05	0.000375	CcSEcCtD
Buprenorphine—Tachycardia—Hydrocortisone—atopic dermatitis	8.7e-05	0.000375	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	8.68e-05	0.000374	CcSEcCtD
Buprenorphine—Flushing—Prednisone—atopic dermatitis	8.67e-05	0.000373	CcSEcCtD
Buprenorphine—Skin disorder—Hydrocortisone—atopic dermatitis	8.66e-05	0.000373	CcSEcCtD
Buprenorphine—Ill-defined disorder—Betamethasone—atopic dermatitis	8.66e-05	0.000373	CcSEcCtD
Buprenorphine—Ill-defined disorder—Dexamethasone—atopic dermatitis	8.66e-05	0.000373	CcSEcCtD
Buprenorphine—Discomfort—Triamcinolone—atopic dermatitis	8.65e-05	0.000373	CcSEcCtD
Buprenorphine—Discomfort—Methylprednisolone—atopic dermatitis	8.63e-05	0.000372	CcSEcCtD
Buprenorphine—Hyperhidrosis—Hydrocortisone—atopic dermatitis	8.62e-05	0.000371	CcSEcCtD
Buprenorphine—Dry mouth—Triamcinolone—atopic dermatitis	8.56e-05	0.000369	CcSEcCtD
Buprenorphine—Angioedema—Dexamethasone—atopic dermatitis	8.53e-05	0.000367	CcSEcCtD
Buprenorphine—Angioedema—Betamethasone—atopic dermatitis	8.53e-05	0.000367	CcSEcCtD
Buprenorphine—Anorexia—Hydrocortisone—atopic dermatitis	8.5e-05	0.000366	CcSEcCtD
Buprenorphine—Nausea—Tacrolimus—atopic dermatitis	8.49e-05	0.000366	CcSEcCtD
Buprenorphine—Angiopathy—Prednisone—atopic dermatitis	8.47e-05	0.000365	CcSEcCtD
Buprenorphine—Confusional state—Methylprednisolone—atopic dermatitis	8.45e-05	0.000364	CcSEcCtD
Buprenorphine—Immune system disorder—Prednisone—atopic dermatitis	8.43e-05	0.000363	CcSEcCtD
Buprenorphine—Malaise—Betamethasone—atopic dermatitis	8.42e-05	0.000363	CcSEcCtD
Buprenorphine—Malaise—Dexamethasone—atopic dermatitis	8.42e-05	0.000363	CcSEcCtD
Buprenorphine—Anaphylactic shock—Triamcinolone—atopic dermatitis	8.39e-05	0.000362	CcSEcCtD
Buprenorphine—Oedema—Triamcinolone—atopic dermatitis	8.39e-05	0.000362	CcSEcCtD
Buprenorphine—Vertigo—Dexamethasone—atopic dermatitis	8.39e-05	0.000361	CcSEcCtD
Buprenorphine—Vertigo—Betamethasone—atopic dermatitis	8.39e-05	0.000361	CcSEcCtD
Buprenorphine—Anaphylactic shock—Methylprednisolone—atopic dermatitis	8.38e-05	0.000361	CcSEcCtD
Buprenorphine—Syncope—Betamethasone—atopic dermatitis	8.37e-05	0.000361	CcSEcCtD
Buprenorphine—Syncope—Dexamethasone—atopic dermatitis	8.37e-05	0.000361	CcSEcCtD
Buprenorphine—Infection—Triamcinolone—atopic dermatitis	8.34e-05	0.000359	CcSEcCtD
Buprenorphine—Hypotension—Hydrocortisone—atopic dermatitis	8.33e-05	0.000359	CcSEcCtD
Buprenorphine—Infection—Methylprednisolone—atopic dermatitis	8.32e-05	0.000359	CcSEcCtD
Buprenorphine—Shock—Triamcinolone—atopic dermatitis	8.26e-05	0.000356	CcSEcCtD
Buprenorphine—Insomnia—Prednisolone—atopic dermatitis	8.26e-05	0.000356	CcSEcCtD
Buprenorphine—Shock—Methylprednisolone—atopic dermatitis	8.24e-05	0.000355	CcSEcCtD
Buprenorphine—Nervous system disorder—Methylprednisolone—atopic dermatitis	8.21e-05	0.000354	CcSEcCtD
Buprenorphine—Loss of consciousness—Dexamethasone—atopic dermatitis	8.2e-05	0.000353	CcSEcCtD
Buprenorphine—Loss of consciousness—Betamethasone—atopic dermatitis	8.2e-05	0.000353	CcSEcCtD
Buprenorphine—Paraesthesia—Prednisolone—atopic dermatitis	8.2e-05	0.000353	CcSEcCtD
Buprenorphine—Tachycardia—Triamcinolone—atopic dermatitis	8.19e-05	0.000353	CcSEcCtD
Buprenorphine—Mental disorder—Prednisone—atopic dermatitis	8.18e-05	0.000352	CcSEcCtD
Buprenorphine—Tachycardia—Methylprednisolone—atopic dermatitis	8.17e-05	0.000352	CcSEcCtD
Buprenorphine—Skin disorder—Methylprednisolone—atopic dermatitis	8.14e-05	0.000351	CcSEcCtD
Buprenorphine—Erythema—Prednisone—atopic dermatitis	8.13e-05	0.00035	CcSEcCtD
Buprenorphine—Malnutrition—Prednisone—atopic dermatitis	8.13e-05	0.00035	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	8.12e-05	0.00035	CcSEcCtD
Buprenorphine—Hyperhidrosis—Triamcinolone—atopic dermatitis	8.12e-05	0.00035	CcSEcCtD
Buprenorphine—Hyperhidrosis—Methylprednisolone—atopic dermatitis	8.1e-05	0.000349	CcSEcCtD
Buprenorphine—Convulsion—Betamethasone—atopic dermatitis	8.09e-05	0.000348	CcSEcCtD
Buprenorphine—Convulsion—Dexamethasone—atopic dermatitis	8.09e-05	0.000348	CcSEcCtD
Buprenorphine—Insomnia—Hydrocortisone—atopic dermatitis	8.06e-05	0.000347	CcSEcCtD
Buprenorphine—Hypertension—Dexamethasone—atopic dermatitis	8.06e-05	0.000347	CcSEcCtD
Buprenorphine—Hypertension—Betamethasone—atopic dermatitis	8.06e-05	0.000347	CcSEcCtD
Buprenorphine—Paraesthesia—Hydrocortisone—atopic dermatitis	8.01e-05	0.000345	CcSEcCtD
Buprenorphine—Myalgia—Betamethasone—atopic dermatitis	7.95e-05	0.000342	CcSEcCtD
Buprenorphine—Myalgia—Dexamethasone—atopic dermatitis	7.95e-05	0.000342	CcSEcCtD
Buprenorphine—Anxiety—Dexamethasone—atopic dermatitis	7.92e-05	0.000341	CcSEcCtD
Buprenorphine—Anxiety—Betamethasone—atopic dermatitis	7.92e-05	0.000341	CcSEcCtD
Buprenorphine—Discomfort—Betamethasone—atopic dermatitis	7.85e-05	0.000338	CcSEcCtD
Buprenorphine—Discomfort—Dexamethasone—atopic dermatitis	7.85e-05	0.000338	CcSEcCtD
Buprenorphine—Dyspepsia—Hydrocortisone—atopic dermatitis	7.85e-05	0.000338	CcSEcCtD
Buprenorphine—Hypotension—Methylprednisolone—atopic dermatitis	7.83e-05	0.000337	CcSEcCtD
Buprenorphine—Pain—Prednisolone—atopic dermatitis	7.81e-05	0.000336	CcSEcCtD
Buprenorphine—Decreased appetite—Hydrocortisone—atopic dermatitis	7.75e-05	0.000334	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	7.7e-05	0.000332	CcSEcCtD
Buprenorphine—Fatigue—Hydrocortisone—atopic dermatitis	7.69e-05	0.000331	CcSEcCtD
Buprenorphine—Vision blurred—Prednisone—atopic dermatitis	7.66e-05	0.00033	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	7.65e-05	0.00033	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	7.63e-05	0.000329	CcSEcCtD
Buprenorphine—Pain—Hydrocortisone—atopic dermatitis	7.62e-05	0.000329	CcSEcCtD
Buprenorphine—Anaphylactic shock—Betamethasone—atopic dermatitis	7.62e-05	0.000328	CcSEcCtD
Buprenorphine—Oedema—Betamethasone—atopic dermatitis	7.62e-05	0.000328	CcSEcCtD
Buprenorphine—Oedema—Dexamethasone—atopic dermatitis	7.62e-05	0.000328	CcSEcCtD
Buprenorphine—Anaphylactic shock—Dexamethasone—atopic dermatitis	7.62e-05	0.000328	CcSEcCtD
Buprenorphine—Insomnia—Triamcinolone—atopic dermatitis	7.59e-05	0.000327	CcSEcCtD
Buprenorphine—Insomnia—Methylprednisolone—atopic dermatitis	7.58e-05	0.000326	CcSEcCtD
Buprenorphine—Infection—Dexamethasone—atopic dermatitis	7.57e-05	0.000326	CcSEcCtD
Buprenorphine—Infection—Betamethasone—atopic dermatitis	7.57e-05	0.000326	CcSEcCtD
Buprenorphine—Ill-defined disorder—Prednisone—atopic dermatitis	7.54e-05	0.000325	CcSEcCtD
Buprenorphine—Paraesthesia—Triamcinolone—atopic dermatitis	7.54e-05	0.000325	CcSEcCtD
Buprenorphine—Feeling abnormal—Prednisolone—atopic dermatitis	7.52e-05	0.000324	CcSEcCtD
Buprenorphine—Paraesthesia—Methylprednisolone—atopic dermatitis	7.52e-05	0.000324	CcSEcCtD
Buprenorphine—Shock—Dexamethasone—atopic dermatitis	7.49e-05	0.000323	CcSEcCtD
Buprenorphine—Shock—Betamethasone—atopic dermatitis	7.49e-05	0.000323	CcSEcCtD
Buprenorphine—Dyspnoea—Triamcinolone—atopic dermatitis	7.48e-05	0.000323	CcSEcCtD
Buprenorphine—Nervous system disorder—Betamethasone—atopic dermatitis	7.47e-05	0.000322	CcSEcCtD
Buprenorphine—Nervous system disorder—Dexamethasone—atopic dermatitis	7.47e-05	0.000322	CcSEcCtD
Buprenorphine—Agitation—Prednisone—atopic dermatitis	7.47e-05	0.000322	CcSEcCtD
Buprenorphine—Tachycardia—Betamethasone—atopic dermatitis	7.43e-05	0.00032	CcSEcCtD
Buprenorphine—Tachycardia—Dexamethasone—atopic dermatitis	7.43e-05	0.00032	CcSEcCtD
Buprenorphine—Angioedema—Prednisone—atopic dermatitis	7.43e-05	0.00032	CcSEcCtD
Buprenorphine—Dyspepsia—Triamcinolone—atopic dermatitis	7.39e-05	0.000318	CcSEcCtD
Buprenorphine—Dyspepsia—Methylprednisolone—atopic dermatitis	7.37e-05	0.000318	CcSEcCtD
Buprenorphine—Hyperhidrosis—Betamethasone—atopic dermatitis	7.36e-05	0.000317	CcSEcCtD
Buprenorphine—Hyperhidrosis—Dexamethasone—atopic dermatitis	7.36e-05	0.000317	CcSEcCtD
Buprenorphine—Feeling abnormal—Hydrocortisone—atopic dermatitis	7.35e-05	0.000317	CcSEcCtD
Buprenorphine—Malaise—Prednisone—atopic dermatitis	7.33e-05	0.000316	CcSEcCtD
Buprenorphine—Vertigo—Prednisone—atopic dermatitis	7.3e-05	0.000315	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	7.29e-05	0.000314	CcSEcCtD
Buprenorphine—Syncope—Prednisone—atopic dermatitis	7.29e-05	0.000314	CcSEcCtD
Buprenorphine—Anorexia—Dexamethasone—atopic dermatitis	7.26e-05	0.000313	CcSEcCtD
Buprenorphine—Anorexia—Betamethasone—atopic dermatitis	7.26e-05	0.000313	CcSEcCtD
Buprenorphine—Urticaria—Prednisolone—atopic dermatitis	7.25e-05	0.000312	CcSEcCtD
Buprenorphine—Fatigue—Triamcinolone—atopic dermatitis	7.24e-05	0.000312	CcSEcCtD
Buprenorphine—Fatigue—Methylprednisolone—atopic dermatitis	7.22e-05	0.000311	CcSEcCtD
Buprenorphine—Pain—Triamcinolone—atopic dermatitis	7.18e-05	0.000309	CcSEcCtD
Buprenorphine—Loss of consciousness—Prednisone—atopic dermatitis	7.14e-05	0.000308	CcSEcCtD
Buprenorphine—Hypotension—Dexamethasone—atopic dermatitis	7.12e-05	0.000307	CcSEcCtD
Buprenorphine—Hypotension—Betamethasone—atopic dermatitis	7.12e-05	0.000307	CcSEcCtD
Buprenorphine—Urticaria—Hydrocortisone—atopic dermatitis	7.08e-05	0.000305	CcSEcCtD
Buprenorphine—Abdominal pain—Hydrocortisone—atopic dermatitis	7.05e-05	0.000304	CcSEcCtD
Buprenorphine—Body temperature increased—Hydrocortisone—atopic dermatitis	7.05e-05	0.000304	CcSEcCtD
Buprenorphine—Convulsion—Prednisone—atopic dermatitis	7.04e-05	0.000303	CcSEcCtD
Buprenorphine—Hypertension—Prednisone—atopic dermatitis	7.02e-05	0.000302	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	6.94e-05	0.000299	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	6.94e-05	0.000299	CcSEcCtD
Buprenorphine—Arthralgia—Prednisone—atopic dermatitis	6.92e-05	0.000298	CcSEcCtD
Buprenorphine—Myalgia—Prednisone—atopic dermatitis	6.92e-05	0.000298	CcSEcCtD
Buprenorphine—Feeling abnormal—Triamcinolone—atopic dermatitis	6.92e-05	0.000298	CcSEcCtD
Buprenorphine—Feeling abnormal—Methylprednisolone—atopic dermatitis	6.9e-05	0.000297	CcSEcCtD
Buprenorphine—Anxiety—Prednisone—atopic dermatitis	6.9e-05	0.000297	CcSEcCtD
Buprenorphine—Insomnia—Dexamethasone—atopic dermatitis	6.89e-05	0.000297	CcSEcCtD
Buprenorphine—Insomnia—Betamethasone—atopic dermatitis	6.89e-05	0.000297	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	6.87e-05	0.000296	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	6.85e-05	0.000295	CcSEcCtD
Buprenorphine—Paraesthesia—Betamethasone—atopic dermatitis	6.84e-05	0.000295	CcSEcCtD
Buprenorphine—Paraesthesia—Dexamethasone—atopic dermatitis	6.84e-05	0.000295	CcSEcCtD
Buprenorphine—Discomfort—Prednisone—atopic dermatitis	6.84e-05	0.000295	CcSEcCtD
Buprenorphine—Hypersensitivity—Prednisolone—atopic dermatitis	6.73e-05	0.00029	CcSEcCtD
Buprenorphine—Dyspepsia—Dexamethasone—atopic dermatitis	6.7e-05	0.000289	CcSEcCtD
Buprenorphine—Dyspepsia—Betamethasone—atopic dermatitis	6.7e-05	0.000289	CcSEcCtD
Buprenorphine—Urticaria—Triamcinolone—atopic dermatitis	6.67e-05	0.000287	CcSEcCtD
Buprenorphine—Urticaria—Methylprednisolone—atopic dermatitis	6.65e-05	0.000287	CcSEcCtD
Buprenorphine—Body temperature increased—Triamcinolone—atopic dermatitis	6.64e-05	0.000286	CcSEcCtD
Buprenorphine—Oedema—Prednisone—atopic dermatitis	6.63e-05	0.000286	CcSEcCtD
Buprenorphine—Anaphylactic shock—Prednisone—atopic dermatitis	6.63e-05	0.000286	CcSEcCtD
Buprenorphine—Abdominal pain—Methylprednisolone—atopic dermatitis	6.62e-05	0.000285	CcSEcCtD
Buprenorphine—Decreased appetite—Dexamethasone—atopic dermatitis	6.62e-05	0.000285	CcSEcCtD
Buprenorphine—Decreased appetite—Betamethasone—atopic dermatitis	6.62e-05	0.000285	CcSEcCtD
Buprenorphine—Infection—Prednisone—atopic dermatitis	6.59e-05	0.000284	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Betamethasone—atopic dermatitis	6.58e-05	0.000283	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	6.58e-05	0.000283	CcSEcCtD
Buprenorphine—Hypersensitivity—Hydrocortisone—atopic dermatitis	6.57e-05	0.000283	CcSEcCtD
Buprenorphine—Fatigue—Dexamethasone—atopic dermatitis	6.57e-05	0.000283	CcSEcCtD
Buprenorphine—Fatigue—Betamethasone—atopic dermatitis	6.57e-05	0.000283	CcSEcCtD
Buprenorphine—Shock—Prednisone—atopic dermatitis	6.53e-05	0.000281	CcSEcCtD
Buprenorphine—Pain—Dexamethasone—atopic dermatitis	6.51e-05	0.000281	CcSEcCtD
Buprenorphine—Pain—Betamethasone—atopic dermatitis	6.51e-05	0.000281	CcSEcCtD
Buprenorphine—Nervous system disorder—Prednisone—atopic dermatitis	6.51e-05	0.00028	CcSEcCtD
Buprenorphine—Tachycardia—Prednisone—atopic dermatitis	6.47e-05	0.000279	CcSEcCtD
Buprenorphine—Skin disorder—Prednisone—atopic dermatitis	6.44e-05	0.000278	CcSEcCtD
Buprenorphine—Hyperhidrosis—Prednisone—atopic dermatitis	6.41e-05	0.000276	CcSEcCtD
Buprenorphine—Asthenia—Hydrocortisone—atopic dermatitis	6.4e-05	0.000276	CcSEcCtD
Buprenorphine—OPRM1—G alpha (i) signalling events—CCR5—atopic dermatitis	6.34e-05	0.00116	CbGpPWpGaD
Buprenorphine—Anorexia—Prednisone—atopic dermatitis	6.32e-05	0.000272	CcSEcCtD
Buprenorphine—Pruritus—Hydrocortisone—atopic dermatitis	6.31e-05	0.000272	CcSEcCtD
Buprenorphine—Feeling abnormal—Betamethasone—atopic dermatitis	6.28e-05	0.00027	CcSEcCtD
Buprenorphine—Feeling abnormal—Dexamethasone—atopic dermatitis	6.28e-05	0.00027	CcSEcCtD
Buprenorphine—OPRM1—GPCR ligand binding—TAC1—atopic dermatitis	6.25e-05	0.00114	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—NPS—atopic dermatitis	6.25e-05	0.00114	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—CCR5—atopic dermatitis	6.23e-05	0.00114	CbGpPWpGaD
Buprenorphine—Gastrointestinal pain—Dexamethasone—atopic dermatitis	6.23e-05	0.000268	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Betamethasone—atopic dermatitis	6.23e-05	0.000268	CcSEcCtD
Buprenorphine—Hypersensitivity—Triamcinolone—atopic dermatitis	6.18e-05	0.000267	CcSEcCtD
Buprenorphine—Hypersensitivity—Methylprednisolone—atopic dermatitis	6.17e-05	0.000266	CcSEcCtD
Buprenorphine—OPRD1—Peptide ligand-binding receptors—CXCL8—atopic dermatitis	6.13e-05	0.00112	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CXCR3—atopic dermatitis	6.13e-05	0.00112	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CCL27—atopic dermatitis	6.1e-05	0.00111	CbGpPWpGaD
Buprenorphine—Diarrhoea—Hydrocortisone—atopic dermatitis	6.1e-05	0.000263	CcSEcCtD
Buprenorphine—Urticaria—Betamethasone—atopic dermatitis	6.05e-05	0.000261	CcSEcCtD
Buprenorphine—Urticaria—Dexamethasone—atopic dermatitis	6.05e-05	0.000261	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Prednisone—atopic dermatitis	6.04e-05	0.00026	CcSEcCtD
Buprenorphine—Dizziness—Prednisolone—atopic dermatitis	6.04e-05	0.00026	CcSEcCtD
Buprenorphine—Asthenia—Triamcinolone—atopic dermatitis	6.02e-05	0.00026	CcSEcCtD
Buprenorphine—Body temperature increased—Betamethasone—atopic dermatitis	6.02e-05	0.000259	CcSEcCtD
Buprenorphine—Abdominal pain—Dexamethasone—atopic dermatitis	6.02e-05	0.000259	CcSEcCtD
Buprenorphine—Body temperature increased—Dexamethasone—atopic dermatitis	6.02e-05	0.000259	CcSEcCtD
Buprenorphine—Abdominal pain—Betamethasone—atopic dermatitis	6.02e-05	0.000259	CcSEcCtD
Buprenorphine—Asthenia—Methylprednisolone—atopic dermatitis	6.01e-05	0.000259	CcSEcCtD
Buprenorphine—Insomnia—Prednisone—atopic dermatitis	6e-05	0.000259	CcSEcCtD
Buprenorphine—OPRL1—Signaling Pathways—NPS—atopic dermatitis	5.99e-05	0.00109	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TAC1—atopic dermatitis	5.99e-05	0.00109	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	5.97e-05	0.00109	CbGpPWpGaD
Buprenorphine—Paraesthesia—Prednisone—atopic dermatitis	5.96e-05	0.000257	CcSEcCtD
Buprenorphine—OPRD1—Signaling by GPCR—CCL11—atopic dermatitis	5.95e-05	0.00108	CbGpPWpGaD
Buprenorphine—Pruritus—Triamcinolone—atopic dermatitis	5.94e-05	0.000256	CcSEcCtD
Buprenorphine—Pruritus—Methylprednisolone—atopic dermatitis	5.93e-05	0.000255	CcSEcCtD
Buprenorphine—Dizziness—Hydrocortisone—atopic dermatitis	5.9e-05	0.000254	CcSEcCtD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	5.89e-05	0.00107	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—FCER2—atopic dermatitis	5.87e-05	0.00107	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CXCR3—atopic dermatitis	5.87e-05	0.00107	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—CXCL10—atopic dermatitis	5.86e-05	0.00107	CbGpPWpGaD
Buprenorphine—Dyspepsia—Prednisone—atopic dermatitis	5.84e-05	0.000252	CcSEcCtD
Buprenorphine—Decreased appetite—Prednisone—atopic dermatitis	5.77e-05	0.000248	CcSEcCtD
Buprenorphine—Rash—Prednisolone—atopic dermatitis	5.76e-05	0.000248	CcSEcCtD
Buprenorphine—OPRD1—GPCR ligand binding—CCL5—atopic dermatitis	5.75e-05	0.00105	CbGpPWpGaD
Buprenorphine—Dermatitis—Prednisolone—atopic dermatitis	5.75e-05	0.000248	CcSEcCtD
Buprenorphine—Diarrhoea—Methylprednisolone—atopic dermatitis	5.73e-05	0.000247	CcSEcCtD
Buprenorphine—Fatigue—Prednisone—atopic dermatitis	5.72e-05	0.000246	CcSEcCtD
Buprenorphine—Headache—Prednisolone—atopic dermatitis	5.72e-05	0.000246	CcSEcCtD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—atopic dermatitis	5.69e-05	0.00104	CbGpPWpGaD
Buprenorphine—Constipation—Prednisone—atopic dermatitis	5.67e-05	0.000244	CcSEcCtD
Buprenorphine—Vomiting—Hydrocortisone—atopic dermatitis	5.67e-05	0.000244	CcSEcCtD
Buprenorphine—Rash—Hydrocortisone—atopic dermatitis	5.62e-05	0.000242	CcSEcCtD
Buprenorphine—Dermatitis—Hydrocortisone—atopic dermatitis	5.62e-05	0.000242	CcSEcCtD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	5.6e-05	0.00102	CbGpPWpGaD
Buprenorphine—Headache—Hydrocortisone—atopic dermatitis	5.59e-05	0.000241	CcSEcCtD
Buprenorphine—OPRL1—Signaling Pathways—IL5—atopic dermatitis	5.57e-05	0.00101	CbGpPWpGaD
Buprenorphine—Dizziness—Triamcinolone—atopic dermatitis	5.55e-05	0.000239	CcSEcCtD
Buprenorphine—Dizziness—Methylprednisolone—atopic dermatitis	5.54e-05	0.000239	CcSEcCtD
Buprenorphine—OPRM1—Signaling by GPCR—CCL17—atopic dermatitis	5.47e-05	0.000997	CbGpPWpGaD
Buprenorphine—Feeling abnormal—Prednisone—atopic dermatitis	5.47e-05	0.000236	CcSEcCtD
Buprenorphine—Asthenia—Betamethasone—atopic dermatitis	5.46e-05	0.000235	CcSEcCtD
Buprenorphine—Asthenia—Dexamethasone—atopic dermatitis	5.46e-05	0.000235	CcSEcCtD
Buprenorphine—OPRD1—Signaling Pathways—CCL22—atopic dermatitis	5.46e-05	0.000995	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—CASP8—atopic dermatitis	5.44e-05	0.000992	CbGpPWpGaD
Buprenorphine—Gastrointestinal pain—Prednisone—atopic dermatitis	5.42e-05	0.000234	CcSEcCtD
Buprenorphine—Nausea—Prednisolone—atopic dermatitis	5.42e-05	0.000234	CcSEcCtD
Buprenorphine—Pruritus—Dexamethasone—atopic dermatitis	5.39e-05	0.000232	CcSEcCtD
Buprenorphine—Pruritus—Betamethasone—atopic dermatitis	5.39e-05	0.000232	CcSEcCtD
Buprenorphine—OPRK1—Peptide ligand-binding receptors—CXCL8—atopic dermatitis	5.38e-05	0.00098	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CCR3—atopic dermatitis	5.34e-05	0.000974	CbGpPWpGaD
Buprenorphine—Vomiting—Triamcinolone—atopic dermatitis	5.34e-05	0.00023	CcSEcCtD
Buprenorphine—Vomiting—Methylprednisolone—atopic dermatitis	5.33e-05	0.000229	CcSEcCtD
Buprenorphine—CYP2C18—Metabolism—GLB1—atopic dermatitis	5.32e-05	0.00097	CbGpPWpGaD
Buprenorphine—Nausea—Hydrocortisone—atopic dermatitis	5.3e-05	0.000228	CcSEcCtD
Buprenorphine—Rash—Triamcinolone—atopic dermatitis	5.29e-05	0.000228	CcSEcCtD
Buprenorphine—Dermatitis—Triamcinolone—atopic dermatitis	5.29e-05	0.000228	CcSEcCtD
Buprenorphine—Rash—Methylprednisolone—atopic dermatitis	5.28e-05	0.000228	CcSEcCtD
Buprenorphine—Dermatitis—Methylprednisolone—atopic dermatitis	5.28e-05	0.000227	CcSEcCtD
Buprenorphine—Urticaria—Prednisone—atopic dermatitis	5.27e-05	0.000227	CcSEcCtD
Buprenorphine—Headache—Triamcinolone—atopic dermatitis	5.26e-05	0.000227	CcSEcCtD
Buprenorphine—Headache—Methylprednisolone—atopic dermatitis	5.25e-05	0.000226	CcSEcCtD
Buprenorphine—Abdominal pain—Prednisone—atopic dermatitis	5.24e-05	0.000226	CcSEcCtD
Buprenorphine—Body temperature increased—Prednisone—atopic dermatitis	5.24e-05	0.000226	CcSEcCtD
Buprenorphine—OPRK1—Signaling by GPCR—CCL11—atopic dermatitis	5.22e-05	0.000951	CbGpPWpGaD
Buprenorphine—Diarrhoea—Betamethasone—atopic dermatitis	5.21e-05	0.000225	CcSEcCtD
Buprenorphine—Diarrhoea—Dexamethasone—atopic dermatitis	5.21e-05	0.000225	CcSEcCtD
Buprenorphine—OPRD1—GPCR ligand binding—CCR5—atopic dermatitis	5.18e-05	0.000944	CbGpPWpGaD
Buprenorphine—OPRD1—G alpha (i) signalling events—CXCL8—atopic dermatitis	5.17e-05	0.000943	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—FCER2—atopic dermatitis	5.15e-05	0.000938	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	5.1e-05	0.00093	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—ADSL—atopic dermatitis	5.1e-05	0.00093	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—atopic dermatitis	5.08e-05	0.000926	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—atopic dermatitis	5.06e-05	0.000922	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—CCL5—atopic dermatitis	5.04e-05	0.000919	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	5.04e-05	0.000919	CbGpPWpGaD
Buprenorphine—Dizziness—Betamethasone—atopic dermatitis	5.04e-05	0.000217	CcSEcCtD
Buprenorphine—Dizziness—Dexamethasone—atopic dermatitis	5.04e-05	0.000217	CcSEcCtD
Buprenorphine—Nausea—Triamcinolone—atopic dermatitis	4.99e-05	0.000215	CcSEcCtD
Buprenorphine—Nausea—Methylprednisolone—atopic dermatitis	4.98e-05	0.000214	CcSEcCtD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	4.97e-05	0.000906	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CXCL10—atopic dermatitis	4.95e-05	0.000902	CbGpPWpGaD
Buprenorphine—Hypersensitivity—Prednisone—atopic dermatitis	4.89e-05	0.000211	CcSEcCtD
Buprenorphine—OPRD1—Signaling Pathways—CCL27—atopic dermatitis	4.86e-05	0.000886	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CCR3—atopic dermatitis	4.85e-05	0.000884	CbGpPWpGaD
Buprenorphine—Vomiting—Betamethasone—atopic dermatitis	4.84e-05	0.000209	CcSEcCtD
Buprenorphine—Vomiting—Dexamethasone—atopic dermatitis	4.84e-05	0.000209	CcSEcCtD
Buprenorphine—Rash—Dexamethasone—atopic dermatitis	4.8e-05	0.000207	CcSEcCtD
Buprenorphine—Rash—Betamethasone—atopic dermatitis	4.8e-05	0.000207	CcSEcCtD
Buprenorphine—Dermatitis—Dexamethasone—atopic dermatitis	4.8e-05	0.000207	CcSEcCtD
Buprenorphine—Dermatitis—Betamethasone—atopic dermatitis	4.8e-05	0.000207	CcSEcCtD
Buprenorphine—OPRK1—Signaling Pathways—CCL22—atopic dermatitis	4.79e-05	0.000872	CbGpPWpGaD
Buprenorphine—Headache—Dexamethasone—atopic dermatitis	4.77e-05	0.000206	CcSEcCtD
Buprenorphine—Headache—Betamethasone—atopic dermatitis	4.77e-05	0.000206	CcSEcCtD
Buprenorphine—OPRD1—GPCR downstream signaling—TAC1—atopic dermatitis	4.76e-05	0.000868	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—NPS—atopic dermatitis	4.76e-05	0.000868	CbGpPWpGaD
Buprenorphine—Asthenia—Prednisone—atopic dermatitis	4.76e-05	0.000205	CcSEcCtD
Buprenorphine—OPRL1—Signaling Pathways—CXCL10—atopic dermatitis	4.75e-05	0.000865	CbGpPWpGaD
Buprenorphine—Pruritus—Prednisone—atopic dermatitis	4.69e-05	0.000202	CcSEcCtD
Buprenorphine—OPRK1—GPCR downstream signaling—CCR3—atopic dermatitis	4.69e-05	0.000854	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CXCR3—atopic dermatitis	4.67e-05	0.000851	CbGpPWpGaD
Buprenorphine—OPRM1—TCR Signaling Pathway—IL6—atopic dermatitis	4.64e-05	0.000846	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—IFNG—atopic dermatitis	4.63e-05	0.000843	CbGpPWpGaD
Buprenorphine—OPRM1—Peptide ligand-binding receptors—CXCL8—atopic dermatitis	4.55e-05	0.000828	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—CCR5—atopic dermatitis	4.54e-05	0.000828	CbGpPWpGaD
Buprenorphine—Diarrhoea—Prednisone—atopic dermatitis	4.54e-05	0.000196	CcSEcCtD
Buprenorphine—OPRK1—G alpha (i) signalling events—CXCL8—atopic dermatitis	4.54e-05	0.000827	CbGpPWpGaD
Buprenorphine—Nausea—Dexamethasone—atopic dermatitis	4.52e-05	0.000195	CcSEcCtD
Buprenorphine—Nausea—Betamethasone—atopic dermatitis	4.52e-05	0.000195	CcSEcCtD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	4.44e-05	0.000809	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—IL5—atopic dermatitis	4.43e-05	0.000807	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CCL11—atopic dermatitis	4.41e-05	0.000804	CbGpPWpGaD
Buprenorphine—Dizziness—Prednisone—atopic dermatitis	4.39e-05	0.000189	CcSEcCtD
Buprenorphine—OPRD1—Signaling Pathways—CCL17—atopic dermatitis	4.36e-05	0.000795	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—FCER2—atopic dermatitis	4.35e-05	0.000793	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—TAC1—atopic dermatitis	4.33e-05	0.000788	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—NPS—atopic dermatitis	4.33e-05	0.000788	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—CXCL8—atopic dermatitis	4.3e-05	0.000784	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCL27—atopic dermatitis	4.27e-05	0.000777	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CCL5—atopic dermatitis	4.26e-05	0.000777	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CCR3—atopic dermatitis	4.26e-05	0.000776	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CXCR3—atopic dermatitis	4.24e-05	0.000773	CbGpPWpGaD
Buprenorphine—Vomiting—Prednisone—atopic dermatitis	4.22e-05	0.000182	CcSEcCtD
Buprenorphine—UGT1A9—Metabolism—GLB1—atopic dermatitis	4.21e-05	0.000766	CbGpPWpGaD
Buprenorphine—Rash—Prednisone—atopic dermatitis	4.18e-05	0.00018	CcSEcCtD
Buprenorphine—Dermatitis—Prednisone—atopic dermatitis	4.18e-05	0.00018	CcSEcCtD
Buprenorphine—OPRK1—GPCR downstream signaling—NPS—atopic dermatitis	4.18e-05	0.000761	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—TAC1—atopic dermatitis	4.18e-05	0.000761	CbGpPWpGaD
Buprenorphine—Headache—Prednisone—atopic dermatitis	4.16e-05	0.000179	CcSEcCtD
Buprenorphine—OPRL1—GPCR downstream signaling—CXCL8—atopic dermatitis	4.15e-05	0.000756	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—IL1B—atopic dermatitis	4.13e-05	0.000752	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	4.11e-05	0.00075	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—IL2—atopic dermatitis	4.11e-05	0.000749	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CXCR3—atopic dermatitis	4.1e-05	0.000746	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CCL5—atopic dermatitis	4.08e-05	0.000744	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	4.07e-05	0.000741	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	4.05e-05	0.000738	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL22—atopic dermatitis	4.04e-05	0.000737	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ADSL—atopic dermatitis	4.03e-05	0.000735	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL5—atopic dermatitis	4.02e-05	0.000733	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—IL2—atopic dermatitis	3.96e-05	0.000722	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CCR3—atopic dermatitis	3.96e-05	0.000722	CbGpPWpGaD
Buprenorphine—Nausea—Prednisone—atopic dermatitis	3.94e-05	0.00017	CcSEcCtD
Buprenorphine—OPRD1—Signaling Pathways—KIF3A—atopic dermatitis	3.89e-05	0.000709	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—IL5—atopic dermatitis	3.88e-05	0.000708	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CCR5—atopic dermatitis	3.84e-05	0.0007	CbGpPWpGaD
Buprenorphine—OPRM1—G alpha (i) signalling events—CXCL8—atopic dermatitis	3.83e-05	0.000699	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCL17—atopic dermatitis	3.83e-05	0.000697	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—TAC1—atopic dermatitis	3.79e-05	0.000691	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—NPS—atopic dermatitis	3.79e-05	0.000691	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—NGF—atopic dermatitis	3.78e-05	0.000689	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CXCL10—atopic dermatitis	3.78e-05	0.000688	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—CXCL8—atopic dermatitis	3.77e-05	0.000686	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CXCR3—atopic dermatitis	3.72e-05	0.000678	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—atopic dermatitis	3.69e-05	0.000672	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—atopic dermatitis	3.69e-05	0.000672	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CCR5—atopic dermatitis	3.68e-05	0.000671	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	3.61e-05	0.000657	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL27—atopic dermatitis	3.6e-05	0.000657	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—IL2—atopic dermatitis	3.6e-05	0.000656	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CCR3—atopic dermatitis	3.6e-05	0.000655	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—GLB1—atopic dermatitis	3.57e-05	0.00065	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—GLB1—atopic dermatitis	3.54e-05	0.000645	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—NPS—atopic dermatitis	3.53e-05	0.000643	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—TAC1—atopic dermatitis	3.53e-05	0.000643	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL5—atopic dermatitis	3.53e-05	0.000643	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CMA1—atopic dermatitis	3.52e-05	0.000641	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCL11—atopic dermatitis	3.52e-05	0.000641	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CXCR3—atopic dermatitis	3.46e-05	0.000631	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	3.46e-05	0.00063	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CXCL10—atopic dermatitis	3.43e-05	0.000625	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ADSL—atopic dermatitis	3.42e-05	0.000624	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KIF3A—atopic dermatitis	3.41e-05	0.000621	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ADSL—atopic dermatitis	3.39e-05	0.000618	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CXCL10—atopic dermatitis	3.31e-05	0.000603	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—STAT6—atopic dermatitis	3.31e-05	0.000603	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—IL5—atopic dermatitis	3.28e-05	0.000598	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CCL5—atopic dermatitis	3.25e-05	0.000592	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GLB1—atopic dermatitis	3.24e-05	0.000591	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL17—atopic dermatitis	3.23e-05	0.000589	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—TAC1—atopic dermatitis	3.21e-05	0.000584	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—NPS—atopic dermatitis	3.21e-05	0.000584	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CXCR3—atopic dermatitis	3.14e-05	0.000573	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—CXCL8—atopic dermatitis	3.13e-05	0.000571	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—NFKBIA—atopic dermatitis	3.12e-05	0.000569	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ADSL—atopic dermatitis	3.11e-05	0.000566	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CMA1—atopic dermatitis	3.08e-05	0.000562	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCL11—atopic dermatitis	3.08e-05	0.000562	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	3.06e-05	0.000559	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	3.05e-05	0.000556	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CXCL10—atopic dermatitis	3.01e-05	0.000548	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—TNF—atopic dermatitis	3e-05	0.000546	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL5—atopic dermatitis	2.98e-05	0.000543	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	2.98e-05	0.000543	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CCL5—atopic dermatitis	2.95e-05	0.000538	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CCR5—atopic dermatitis	2.93e-05	0.000534	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STAT6—atopic dermatitis	2.9e-05	0.000528	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KIF3A—atopic dermatitis	2.88e-05	0.000525	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCR3—atopic dermatitis	2.87e-05	0.000522	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CCL5—atopic dermatitis	2.85e-05	0.000519	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CXCL10—atopic dermatitis	2.8e-05	0.00051	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	2.76e-05	0.000503	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—CXCL8—atopic dermatitis	2.75e-05	0.000501	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	2.69e-05	0.000489	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CCR5—atopic dermatitis	2.66e-05	0.000485	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL11—atopic dermatitis	2.61e-05	0.000475	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CMA1—atopic dermatitis	2.61e-05	0.000475	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CCL5—atopic dermatitis	2.59e-05	0.000472	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CCR5—atopic dermatitis	2.57e-05	0.000468	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GLB1—atopic dermatitis	2.56e-05	0.000466	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NPS—atopic dermatitis	2.56e-05	0.000466	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TAC1—atopic dermatitis	2.56e-05	0.000466	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CXCL10—atopic dermatitis	2.54e-05	0.000463	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCR3—atopic dermatitis	2.51e-05	0.000458	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCR3—atopic dermatitis	2.51e-05	0.000457	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—PPARA—atopic dermatitis	2.47e-05	0.000451	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ADSL—atopic dermatitis	2.45e-05	0.000447	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STAT6—atopic dermatitis	2.45e-05	0.000447	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CCL5—atopic dermatitis	2.41e-05	0.000439	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL5—atopic dermatitis	2.38e-05	0.000433	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CCR5—atopic dermatitis	2.33e-05	0.000425	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CXCL8—atopic dermatitis	2.32e-05	0.000423	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NPS—atopic dermatitis	2.24e-05	0.000408	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TAC1—atopic dermatitis	2.24e-05	0.000408	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CXCL8—atopic dermatitis	2.22e-05	0.000405	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GLB1—atopic dermatitis	2.21e-05	0.000404	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCR3—atopic dermatitis	2.2e-05	0.0004	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CCL5—atopic dermatitis	2.19e-05	0.000399	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CCR5—atopic dermatitis	2.17e-05	0.000395	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IL2—atopic dermatitis	2.13e-05	0.000387	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCR3—atopic dermatitis	2.12e-05	0.000387	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ADSL—atopic dermatitis	2.12e-05	0.000387	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—IL6—atopic dermatitis	2.12e-05	0.000386	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL5—atopic dermatitis	2.08e-05	0.00038	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCL10—atopic dermatitis	2.03e-05	0.000369	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GLB1—atopic dermatitis	1.98e-05	0.00036	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CCR5—atopic dermatitis	1.97e-05	0.000359	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—MAPK8—atopic dermatitis	1.96e-05	0.000357	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GLB1—atopic dermatitis	1.93e-05	0.000352	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ADSL—atopic dermatitis	1.9e-05	0.000345	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NPS—atopic dermatitis	1.89e-05	0.000345	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TAC1—atopic dermatitis	1.89e-05	0.000345	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	1.87e-05	0.00034	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCR3—atopic dermatitis	1.86e-05	0.000338	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ADSL—atopic dermatitis	1.85e-05	0.000337	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GLB1—atopic dermatitis	1.82e-05	0.000331	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GLB1—atopic dermatitis	1.8e-05	0.000328	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCL10—atopic dermatitis	1.78e-05	0.000324	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CXCL8—atopic dermatitis	1.77e-05	0.000323	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL5—atopic dermatitis	1.76e-05	0.000321	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCL5—atopic dermatitis	1.74e-05	0.000318	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ADSL—atopic dermatitis	1.74e-05	0.000318	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ADSL—atopic dermatitis	1.73e-05	0.000315	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PPARA—atopic dermatitis	1.73e-05	0.000315	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—IL2—atopic dermatitis	1.69e-05	0.000308	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NGF—atopic dermatitis	1.61e-05	0.000294	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.61e-05	0.000294	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CXCL8—atopic dermatitis	1.61e-05	0.000293	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCR5—atopic dermatitis	1.57e-05	0.000286	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CXCL8—atopic dermatitis	1.55e-05	0.000283	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GLB1—atopic dermatitis	1.54e-05	0.000281	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL2—atopic dermatitis	1.54e-05	0.00028	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCL5—atopic dermatitis	1.53e-05	0.000279	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL10—atopic dermatitis	1.5e-05	0.000274	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—IL2—atopic dermatitis	1.48e-05	0.00027	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	1.48e-05	0.000269	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ADSL—atopic dermatitis	1.48e-05	0.000269	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.44e-05	0.000263	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NGF—atopic dermatitis	1.42e-05	0.000258	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CXCL8—atopic dermatitis	1.41e-05	0.000257	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCR5—atopic dermatitis	1.38e-05	0.000251	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PPARA—atopic dermatitis	1.36e-05	0.000249	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL2—atopic dermatitis	1.35e-05	0.000246	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	1.34e-05	0.000244	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NFKBIA—atopic dermatitis	1.33e-05	0.000243	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.31e-05	0.000239	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CXCL8—atopic dermatitis	1.31e-05	0.000239	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL5—atopic dermatitis	1.29e-05	0.000235	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—IL2—atopic dermatitis	1.25e-05	0.000228	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IL6—atopic dermatitis	1.25e-05	0.000228	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NGF—atopic dermatitis	1.2e-05	0.000218	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CXCL8—atopic dermatitis	1.19e-05	0.000217	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GLB1—atopic dermatitis	1.19e-05	0.000217	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NFKBIA—atopic dermatitis	1.17e-05	0.000213	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCR5—atopic dermatitis	1.16e-05	0.000212	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PPARA—atopic dermatitis	1.16e-05	0.000211	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PPARA—atopic dermatitis	1.15e-05	0.000209	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ADSL—atopic dermatitis	1.14e-05	0.000208	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL2—atopic dermatitis	1.14e-05	0.000207	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.12e-05	0.000205	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PPARA—atopic dermatitis	1.05e-05	0.000192	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NFKBIA—atopic dermatitis	9.87e-06	0.00018	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCL8—atopic dermatitis	9.5e-06	0.000173	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL2—atopic dermatitis	9.08e-06	0.000165	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL6—atopic dermatitis	9.03e-06	0.000165	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK8—atopic dermatitis	8.35e-06	0.000152	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCL8—atopic dermatitis	8.33e-06	0.000152	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PPARA—atopic dermatitis	8.3e-06	0.000151	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL2—atopic dermatitis	7.96e-06	0.000145	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL6—atopic dermatitis	7.92e-06	0.000144	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK8—atopic dermatitis	7.33e-06	0.000133	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPARA—atopic dermatitis	7.19e-06	0.000131	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL8—atopic dermatitis	7.04e-06	0.000128	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL2—atopic dermatitis	6.73e-06	0.000123	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL6—atopic dermatitis	6.69e-06	0.000122	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARA—atopic dermatitis	6.42e-06	0.000117	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARA—atopic dermatitis	6.26e-06	0.000114	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK8—atopic dermatitis	6.19e-06	0.000113	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARA—atopic dermatitis	5.9e-06	0.000108	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARA—atopic dermatitis	5.85e-06	0.000107	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL6—atopic dermatitis	5.33e-06	9.72e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARA—atopic dermatitis	5e-06	9.11e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6—atopic dermatitis	4.68e-06	8.52e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6—atopic dermatitis	3.95e-06	7.2e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARA—atopic dermatitis	3.86e-06	7.03e-05	CbGpPWpGaD
